CGN Power 1H net income 5.95 billion yuan

CGN Power 1H net income 5.95 billion yuan

CGN Power Co., Ltd. has released its financial results for the first half of 2025, revealing a robust performance with a significant increase in net income. The company reported a net income of 5.95 billion yuan for the period, marking a substantial improvement over previous quarters [1].

Key financial highlights include a total revenue of 11.8 billion yuan, representing a 45% year-on-year increase. This growth was driven by strong sales in both the US and Europe, with the company's core product, Zebutinib, achieving high-speed market penetration. Global sales revenue for Zebutinib reached 0.95 billion USD, up by 49% year-on-year and 20% month-on-month [1].

The company's other important commercial product, Relizumab, also showed steady growth, with total revenue of 0.194 billion USD, up 22% year-on-year and 13% month-on-month [1].

CGN Power Co., Ltd. has also outlined several key milestones for the next 18 months, including the expected approval of the marketing application for Tirelizumab and the initiation of phase III clinical trials for various drugs [1].

The company's strong financial performance is expected to continue, with forecasts indicating revenue of 38, 45.91, and 54.041 billion yuan for the years 2025, 2026, and 2027, respectively. The net income is projected to reach 17.93, 43.13, and 6.79 billion yuan over the same period [1].

Despite the positive outlook, the company acknowledges potential risks, including policy changes, global market risks, and the possibility of R&D progress falling short of expectations [1].

Reference List:
[1] https://news.futunn.com/post/60936380/beigene-688235-q2-2025-profits-significantly-exceed-expectations-with-positive